GLPBio

Immunology/Inflammation

Read More about this category

The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.

Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].

BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].

Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.

Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].

 

References

[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.

[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.

[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.

[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.

[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.

[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.

[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.

[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.

Research Areas

Products Related to Immunology/Inflammation(4960)

  • GC81041 structure
    GC81041GP262
    CAS: 3107761-81-6
    Purity: >98.50%

    GP262 is a PI3K/mTOR PROTAC degrader targeting PI3Kγ, PI3Kα and mTOR with DC 50 values of 42.23 nM, 227.4 nM and 45.4 nM, respectively in MDA-MB-231 cells.

  • GC81297 structure
    GC81297DFCI-002-06
    CAS: 3092208-36-8
    Purity: >98.00%

    DFCI-002-06 is an orally active dual-target HCK/BTK PROTAC degrader with DC₅₀ values for HCK and BTK of 1.3 and 4.5 nM respectively.

  • GC81298 structure
    GC81298BSJ-05-037
    CAS: 2756388-01-7
    Purity: >99.50%

    BSJ-05-037 is an ITK PROTAC degrader that effectively targets and degrades ITK in T-cell lymphoma cell lines.

  • GC81304 structure
    GC81304GW296115
    CAS: 118458-58-5
    Purity: >98.50%

    GW296115 is a multi-target inhibitor with the following IC 50 values against its targets: 8.4 nM for BRSK2, 21 nM for BRSK1, 1.8 μM for PDGFRβ, 5.5 nM for STK17B/DRAK2, 28 nM for DRAK1, 20 nM for PHKG1, and 89 nM for DCAMKL3.

  • GC81305 structure
    GC81305Tyrosine kinase-IN-11
    CAS: 3031972-21-8
    Purity: >98.50%

    Tyrosine kinase-IN-11 (Compound 4b) is a tyrosine kinase inhibitor.

  • GC81306 structure
    GC81306PRT-060318 dihydrochloride
    CAS: 3032567-93-1
    Purity: >98.50%

    PRT-060318 (PRT318) dihydrochloride is a potent, selective and orally active tyrosine kinase Syk inhibitor with an IC 50 of 3 nM.

  • GC81312 structure
    GC81312PARP1/c-Met-IN-3
    CAS: 3123529-62-1
    Purity: >98.00%

    PARP1/c-Met-IN-3 (Compound L19) is a selective c-Met and PARP1 inhibitor, with an IC 50 of 5.4 nM against c-Met and an IC 50 of 3.7 nM against PARP1.

  • GC81314 structure
    GC81314OM-RCA-01
    Purity: >99.00%

    OM-RCA-01 is an anti- FGFR1 monoclonal antibody with a K d of 1.59 nM for human FGFR1.

  • GC81320 structure
    GC81320Papaveroline
    CAS: 574-77-6
    Purity: >98.00%

    Papaveroline is a Fyn tyrosine kinase inhibitor, Na +,K + -ATPase inhibitor with an IC 50 of 0.20 mM, Mg 2+ -ATPase inhibitor, K + -activated pNPPase inhibitor with an IC 50 of 1.51 mM, and apoptosis inducer [1] [2] [3] . Papaveroline binds to the active site of Fyn tyrosine kinase and forms stable interactions with pocket amino acid residues [1] . Papaveroline induces cell apoptosis, produces pycnotic and fragmented cell nuclei, and does not reduce intracellular ATP levels [3] . Papaveroline is a dopamine-derived neurotoxin candidate associated with the pathogenesis of Parkinson's disease [3] . Papaveroline can be used in the research of Alzheimer's disease and Parkinson's disease [3] .

  • GC81322 structure
    GC81322PF-07245303
    CAS: 2655556-75-3
    Purity: >98.00%

    PF-07245303 is a ITK / TRK inhibitor.

  • GC81323 structure
    GC81323PDGFRA/CAIX/XII-IN-1
    Purity: >98.00%

    PDGFRA/CAIX/XII-IN-1 is an inhibitor of PDGFRA, CA IX and CA XII, with an IC 50 of 20 nM against PDGFRA, a K i of 93.3 nM against CA IX, and a K i of 80.0 nM against CA XII.

  • GC81324 structure
    GC81324FGF7p
    CAS: 2758194-43-1
    Purity: >99.00%

    FGF7p is a small molecule peptide and a potential bladder protector.

  • GC81328 structure
    GC81328GZD-552
    Purity: >98.00%

    GZD-552 is a potent orally active FAK inhibitor with a human FAK IC 50 of 5.8 nM.

  • GC81335 structure
    GC81335MST3-IN-1 TFA
    Purity: >99.00%

    MST3-IN-1 TFA (Compound LD-1) is a selective and orally active MST3 inhibitor, with an IC 50 of 122.4 nM.

  • GC81350 structure
    GC81350THR-123 TFA
    Purity: >99.50%

    THR-123 TFA is an orally active ALK3 peptide agonist.

  • GC81392 structure
    GC813928-Oxo-dGTP trisodium solution (100 mM)
    Purity: >98.50%

    8-Oxo-dGTP (8-Oxo-Deoxyguanosine triphosphate) trisodium solution (100mM) is an oxidized guanine nucleotide formed by ROS-mediated oxidative modification of dGTP, and it also serves as a key substrate for 8-oxo-dGTP pyrophosphohydrolases (such as hMTH1 and E.

  • GC81424 structure
    GC81424OMTX005
    Purity: >98.00%

    OMTX005 (OMTX705 antibody) is a humanized anti- FAP IgG1 monoclonal antibody that specifically binds to human ( EC 50: 0.33 nM)/mouse ( EC 50: 0.14 nM) FAP proteins and FAP-positive cells.

  • GC81425 structure
    GC81425Sutantatug
    CAS: 3049680-24-9
    Purity: >99.50%

    Sutantatug (SYS6002 Antibody) is a monoclonal antibody targeting Nectin-4, and serves as the antibody moiety of the ADC CRB-701.

  • GC81426 structure
    GC81426EBC-129 Antibody
    Purity: >99.00%

    EBC-129 Antibody is a specific antibody for the synthetic antibody-drug conjugate (ADC) EBC-129, which specifically targets CEACAM5 and CEACAM6 glycosylated at N256.

  • GC81430 structure
    GC814303-Hydroxyindole
    CAS: 480-93-3
    Purity: >87.50%

    3-Hydroxyindole is a hydroxyindole compound.

  • GC81437 structure
    GC81437Avenanthramide 1c
    CAS: 116764-16-0
    Purity: >98.00%

    Avenanthramide 1c is a free radical scavenger and antioxidant.

  • GC81438 structure
    GC81438Tyrosinase-IN-50
    CAS: 3081328-14-2
    Purity: >99.50%

    Tyrosinase-IN-50 (Compound 14) is a Tyrosinase inhibitor ( IC 50 is 0.06 μM or 0.16 μM).

  • GC81439 structure
    GC81439SZ0232
    CAS: 924851-91-2
    Purity: >99.00%

    SZ0232 is a selective mPGES-2 inhibitor.

  • GC81440 structure
    GC81440Luteolin 7-O-(6-O-malonyl-β-D-glucoside)
    CAS: 98767-38-5
    Purity: >98.00%

    Luteolin 7-O-(6-O-malonyl-β-D-glucoside) is an orally active flavonoid free radical scavenger.